RT Journal Article
SR Electronic
T1 Harnessing methods, data analysis, and near-real-time wastewater monitoring for enhanced public health response using high throughput sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.10.24318772
DO 10.1101/2024.12.10.24318772
A1 Ramachandran, Padmini
A1 Kayikcioglu, Tunc
A1 Walsky, Tamara
A1 Judy, Kathryn
A1 Amirzadegan, Jasmine
A1 Bias, Candace Hope
A1 Tesfaldet, Bereket
A1 Balkey, Maria
A1 EppSchmidt, Dietrich
A1 Rand, Hugh
A1 Pettengill, James
A1 Tallent, Sandra
A1 Brown, Eric
A1 Pfefer, Tina
A1 Timme, Ruth
A1 Windsor, Amanda
A1 Grim, Christopher
A1 Hoffmann, Maria
YR 2024
UL http://medrxiv.org/content/early/2024/12/11/2024.12.10.24318772.abstract
AB Wastewater-based analysis has emerged as a pivotal method for monitoring SARS-CoV-2 (SC2). Leveraging high-throughput sequencing on wastewater samples facilitates a comprehensive, population-level assessment of circulating and emerging SC2 variants within a community. This study meticulously evaluates the detection performance, variant calling accuracy, and the time taken from sample collection to public data release for wastewater SC2 monitoring. We employed two different SC2 target enrichment panels on Illumina MiSeq and Oxford Nanopore Technologies (ONT) GridION sequencing platforms for a robust analysis. Daily collection of routine raw grab and composite samples took place at a wastewater treatment plant (WWTP) site in Maryland, USA (MD) from mid-January 2022 to the end of June 2022. Total Nucleic Acid (TNA) was extracted from samples and target enrichment was executed using QIAseq DIRECT and NEBNext VarSkip Short amplicon kits, with subsequent sequencing on MiSeq or ONT GridION platforms, respectively. Obtained sequences was analyzed using our custom CFSAN Wastewater Analysis Pipeline (C-WAP). Raw sequence data and detailed metadata were submitted to NCBI (BioProject PRJNA757291) as it became available. Our wastewater data successfully detected the onset of new variants BA.2, BA.2.12, BA.4.6, and BA.5 to the observed population. Notably, Omicron sub-variants were identified approximately a week ahead of publicly available clinical data at the MD ZIP-code level. Variation in quality metrics paralleled the rise and fall of BA waves, underscoring the impact of viral load on sequencing quality. Regular updates of estimated variant proportions were made available on the FDA-CFSAN “Wastewater Surveillance for SARS-CoV-2 Variants” website. In contrast to the median 28-day turnaround for our samples, the lead time from sample collection to public release of raw sequence data via NCBI was remarkably swift, accomplished within a mere 57 hours in this specific exercise. Our processing, sequencing, and analysis methods empowered the swift and accurate detection of SC2 trends and circulating variants within a community, offering insights for public health decision-making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData generated in this study were deposited in the NCBI BioProject database under the BioProject accession number PRJNA757291.SC2SARS-CoV-2WWTPWastewater treatment plantTNATotal Nucleic AcidC-WAPCFSAN Wastewater Analysis Pipeline